Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y

Cell Death and Differentiation

Volumn 20, Issue 5, 2013, Pages 676-685

  Dolfini, D ^a   Mantovani, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

CCAAT box; NF Y; Y box; YB 1

Indexed keywords

COLLAGENASE 3; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; GELATINASE A; HERMES ANTIGEN; HLA DR ANTIGEN; MACROPHAGE ELASTASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; NUCLEAR FACTOR Y; PROTEIN P53; RANTES; RNA POLYMERASE II; SCATTER FACTOR RECEPTOR; SMAD7 PROTEIN; VASCULOTROPIN; Y BOX BINDING PROTEIN 1;

ALPHA HELIX; BINDING SITE; CANCER CELL; CELL CYCLE G2 PHASE; CELLULAR DISTRIBUTION; CPG ISLAND; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENOME; IN VITRO STUDY; LONG TERMINAL REPEAT; MUTAGENESIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; XENOPUS;

ANIMALS; CCAAT-BINDING FACTOR; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; TRANSCRIPTIONAL ACTIVATION; Y-BOX-BINDING PROTEIN 1;

EID: 84877584214     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.13     Document Type: Review

References (140)

1. Mathis DJ, Benoist CO, Williams VE II, Kanter MR, McDevitt HO. The murine E alpha immune response gene. Cell 1983; 32: 745-754.
2. Benoist C, Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol 1990; 8: 681-715.
3. Efstratiadis A, Posakony JW, Maniatis T, Lawn RM, O'Connell C, Spritz RA et al. The structure and evolution of the human beta-globin gene family. Cell 1980; 21: 653-668.
4. Grosveld GC, Shewmaker CK, Jat P, Flavell RA. Localization of DNA sequences necessary for transcription of the rabbit beta-globin gene in vitro. Cell 1981; 25: 215-226.
5. Myers RM, Tilly K, Maniatis T. Fine structure genetic analysis of a beta-globin promoter. Science 1986; 232: 613-618.
6. Maity SN, Golumbek PT, Karsenty G, de Crombrugghe B. Selective activation of transcription by a novel CCAAT binding factor. Science 1988; 241: 582-585.
7. Kim CG, Sheffery M. Physical characterization of the purified CCAAT transcription factor, alpha-CP1. J Biol Chem 1990; 265: 13362-13369.
8. Greuel BT, Sealy L, Majors JE. Transcriptional activity of the Rous sarcoma virus long terminal repeat correlates with binding of a factor to an upstream CCAAT box in vitro. Virology 1990; 177: 33-43.
9. Viville S, Jongeneel V, Koch W, Mantovani R, Benoist C, Mathis D. The E alpha promoter: a linker-scanning analysis. J Immunol 1991; 146: 3211-3217.
10. Tronche F, Rollier A, Sourdive D, Cereghini S, Yaniv M. NFY or a related CCAAT binding factor can be replaced by other transcriptional activators for co-operation with HNF1 in driving the rat albumin promoter in vivo. J Mol Biol 1991; 222: 31-43.
11. Zeleznik-Le NJ, Azizkhan JC, Ting JP. Affinity-purified CCAAT-box-binding protein (YEBP) functionally regulates expression of a human class II major histocompatibility complex gene and the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1991; 88: 1873-1877.
12. Suzuki Y, Tsunoda T, Sese J, Taira H, Mizushima-Sugano J, Hata H et al. Identification and characterization of the potential promoter regions of 1031 kinds of human genes. Genome Res 2001; 11: 677-684.
13. Suzuki Y, Yamashita R, Shirota M, Sakakibara Y, Chiba J, Mizushima-Sugano J et al. Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions. Genome Res 2004; 14: 1711-1718.
14. Elkon R, Linhart C, Sharan R, Shamir R, Shiloh Y. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res 2003; 13: 773-780.
15. Linhart C, Elkon R, Shiloh Y, Shamir R. Deciphering transcriptional regulatory elements that encode specific cell cycle phasing by comparative genomics analysis. Cell Cycle 2005; 4: 1788-1797.
16. Zhu Z, Shendure J, Church GM. Discovering functional transcription-factor combinations in the human cell cycle. Genome Res 2005; 15: 848-855.
17. Grskovic M, Chaivorapol C, Gaspar-Maia A, Li H, Ramalho-Santos M. Systematic identification of cis-regulatory sequences active in mouse and human embryonic stem cells. PLoS Genet 2007; 3: e145.
18. Halperin Y, Linhart C, Ulitsky I, Shamir R. Allegro: analyzing expression and sequence in concert to discover regulatory programs. Nucleic Acids Res 2009; 37: 1566-1579.
19. Häkkinen A, Healy S, Jacobs HT, Ribeiro AS. Genome wide study of NF-Y type CCAAT boxes in unidirectional and bidirectional promoters in human and mouse. J Theor Biol 2011; 281: 74-83.
20. Marino-Ramrez L, Spouge JL, Kanga GC, Landsman D. Statistical analysis of over-represented words in human promoter sequences. Nucleic Acids Res 2004; 32: 949-958.
21. Fitzgerald PC, Shlyakhtenko A, Mir AA, Vinson C. Clustering of DNA sequences in human promoters. Genome Res 2004; 14: 1562-1574.
22. Tabach Y, Milyavsky M, Shats I, Brosh R, Zuk O, Yitzhaky A et al. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol 2005; 1: 0022.
23. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007; 67: 10148-10158.
24. Scafoglio C, Ambrosino C, Cicatiello L, Altucci L, Ardovino M, Bontempo P et al. Comparartive gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem 2006; 98: 1163-1184.
25. Niida A, Smith AD, Imoto S, Tsutsumi S, Aburatani H, Zhang MQ et al. Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells. BMC Bioinform 2008; 9: 404.
26. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies metastatic pathways and transcription factors in cancer. BMC Cancer 2008; 8: 394.
27. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X et al. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One 2009; 4: e5722.
28. Calvo A, Perez-Stable C, Segura V, Catena R, Guruceaga E, Nguewa P et al. Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer. Prostate 2010; 70: 630-645.
29. Forsberg EC, Passegué E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM et al. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS One 2010; 5: e8785.
30. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G et al. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 2007; 67: 3320-3328.
31. Yamanaka K, Mizuarai S, Eguchi T, Itadani H, Hirai H, Kotani H. Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics 2009; 94: 219-227.
32. Goodarzi H, Elemento O, Tavazoie S. Revealing global regulatory perturbations across human cancers. Mol Cell 2009; 36: 900-911.
33. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005; 37: 579-583.
34. Sinha S, Adler AS, Field Y, Chang HY, Segal E. Systematic functional characterization of cis-regulatory motifs in human core promoters. Genome Res 2008; 18: 477-488.
35. Dorn A, Bollekens J, Staub A, Benoist C, Mathis D. A multiplicity of CCAAT box-binding proteins. Cell 1987; 50: 863-672.
36. Osada S, Matsubara T, Daimon S, Terazu Y, Xu M, Nishihara T et al. Expression, DNAbinding specificity and transcriptional regulation of nuclear factor 1 family proteins from rat. Biochem J 1999; 342: 189-198.
37. Osada S, Yamamoto H, Nishihara T, Imagawa M. DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem 1996; 271: 3891-3896.
38. Roulet E, Busso S, Camargo AA, Simpson AJ, Mermod N, Bucher P. High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites. Nat Biotechnol 2002; 20: 831-835.
39. Hooft van Huijsduijnen RA, Bollekens J, Dorn A, Benoist C, Mathis D. Properties of a CCAAT box-binding protein. Nucleic Acids Res 1987; 15: 7265-7282.
40. Faber M, Sealy L. Rous sarcoma virus enhancer factor I is a ubiquitous CCAAT transcription factor highly related to CBF and NF-Y. J Biol Chem 1990; 265: 22243-22254.
41. Chodosh LA, Olesen J, Hahn S, Baldwin AS, Guarente L, Sharp PA. A yeast and a human CCAAT-binding protein have heterologous subunits that are functionally interchangeable. Cell 1988; 53: 25-35.
42. Hatamochi A, Golumbek PT, Maity SN, de Crombrugghe B. A CCAAT DNA binding factor consisting of two different components that are both required for DNA binding. J Biol Chem 1988; 263: 5940-5947.
43. Vuorio T, Maity SN, de Crombrugghe B. Purification and molecular cloning of the 'A' chain of a rat heteromeric CCAAT-binding protein. Sequence identity with the yeast HAP3 transcription factor. J Biol Chem 1990; 265: 22480-22486.
44. Maity SN, Vuorio T, de Crombrugghe B. The B subunit of a rat heteromeric CCAATbinding transcription factor shows a striking sequence identity with the yeast Hap2 transcription factor. Proc Natl Acad Sci USA 1990; 87: 5378-5382.
45. Hooft van Huijsduijnen R, Li XY, Black D, Matthes H, Benoist C, Mathis D. Co-evolution from yeast to mouse: cDNA cloning of the two NF-Y (CP-1/CBF) subunits. EMBO J 1990; 9: 3119-3127.
46. Romier C, Cocchiarella F, Mantovani R, Moras D. The NF-YB/NF-YC structure gives insight into DNA binding and transcription regulation by CCAAT factor NF-Y. J Biol Chem 2003; 278: 1336-1345.
47. Bi W, Wu L, Coustry F, de Crombrugghe B, Maity SN. DNA binding specificity of the CCAAT-binding factor CBF/NF-Y. J Biol Chem 1997; 272: 26562-26572.
48. Mantovani R, Pessara U, Tronche F, Li XY, Knapp AM, Pasquali JL et al. Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription. EMBO J 1992; 11: 3315-3322.
49. Coustry F, Maity SN, de Crombrugghe B. Studies on transcription activation by the multimeric CCAAT-binding factor CBF. J Biol Chem 1995; 270: 468-475.
50. Coustry F, Hu Q, de Crombrugghe B, Maity SN. CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase IIalpha promoter. Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure. J Biol Chem 2001; 276: 40621-40630.
51. Coustry F, Maity SN, Sinha S, de Crombrugghe B. The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit. J Biol Chem 2006; 271: 14485-14491.
52. Bennett MK, Osborne TF. Nutrient regulation of gene expression by the sterol regulatory element binding proteins: increased recruitment of gene-specific coregulatory factors and selective hyperacetylation of histone H3 in vivo. Proc Natl Acad Sci USA 2000; 97: 6340-6344.
53. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res 1998; 26: 1135-1143.
54. Mantovani R, Li XY, Pessara U, Hooft van HR, Benoist C, Mathis D. Dominant negative analogs of NF-YA. J Biol Chem 1994; 269: 20340-20346.
55. Dolfini D, Zambelli F, Pavesi G, Mantovani R. A perspective of promoter architecture from the CCAAT box. Cell Cycle 2009; 8: 4127-4137.
56. Testa A, Donati G, Yan P, Romani F, Huang TH, Viganò MA et al. Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters. J Biol Chem 2005; 280: 13606-13615.
57. Ceribelli M, Alcalay M, Vigano MA, Mantovani R. Repression of new p53 targets revealed by ChIP on chip experiments. Cell Cycle 2006; 5: 1102-1110.
58. Ceribelli M, Dolfini D, Merico D, Gatta R, Viganò AM, Pavesi G et al. The histone-like NFY is a bifunctional transcription factor. Mol Cell Biol 2008; 28: 2047-2058.
59. Reed BD, Charos AE, Szekely AM, Weissman SM, Snyder M. Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes. PLoS Genet 2008; 4: e1000133.
60. Wang J, Zhuang J, Iyer S, Lin X, Whitfield TW, Greven MC et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res 2012; 22: 1798-1812.
61. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 1988; 85: 7322-7326.
62. Ozer J, Faber M, Chalkley R, Sealy L. Isolation and characterization of a cDNA clone for the CCAAT transcription factor EFIA reveals a novel structural motif. J Biol Chem 1990; 265: 22143-22152.
63. Tafuri SR, Wolffe AP. Xenopus Y-box transcription factors: molecular cloning, functional analysis and developmental regulation. Proc Natl Acad Sci USA 1990; 87: 9028-9032.
64. Grant CE, Deeley RG. Cloning and characterization of chicken YB-1: regulation of expression in the liver. Mol Cell Biol 1993; 13: 4186-4196.
65. Mihailovich M, Militti C, Gabaldon T, Gebauer F. Eukaryotic cold shock domain proteins: highly versatile regulators of gene expression. Bioessays 2010; 32: 109-118.
66. Hasegawa SL, Doetsch PW, Hamilton KK, Martin AM, Okenquist SA, Lenz J et al. DNA binding properties of YB-1 and dbpA: binding to double-stranded, single-stranded, and abasic site containing DNAs. Nucleic Acids Res 1991; 19: 4915-4920.
67. Murray MT, Schiller DL, Franke WW. Sequence analysis of cytoplasmic mRNA-binding proteins of Xenopus oocytes identifies a family of RNA-binding proteins. Proc Natl Acad Sci USA 1992; 89: 11-15.
68. Minich WB, Ovchinnikov LP. Role of cytoplasmic mRNP proteins in translation. Biochimie 1992; 74: 477-483.
69. Bouvet P, Wolffe AP. A role for transcription and FRGY2 in masking maternal mRNA within Xenopus oocytes. Cell 1994; 77: 931-941.
70. Evdokimova V, Ovchinnikov LP, Sorensen PH. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 2006; 5: 1143-1147.
71. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry 2011; 76: 1402-1433.
72. Bouvet P, Matsumoto K, Wolffe AP. Sequence-specific RNA recognition by the Xenopus Y-box proteins. An essential role for the cold shock domain. J Biol Chem 1995; 270: 28297-28303.
73. Zasedateleva OA, Krylov AS, Prokopenko DV, Skabkin MA, Ovchinnikov LP, Kolchinsky A et al. Specificity of mammalian Y-box binding protein p50 in interaction with ss and ds DNA analyzed with generic oligonucleotide microchip. J Mol Biol 2002; 324: 73-87.
74. Ray D, Kazan H, Chan ET, Peña Castillo L, Chaudhry S, Talukder S et al. Rapid and systematic analysis of the RNA recognition specificities of RNA-binding proteins. Nat Biotechnol 2009; 27: 667-670.
75. Liberati C, di Silvio A, Ottolenghi S, Mantovani R. NF-Y binding to twin CCAAT boxes: role of Q-rich domains and histone fold helices. J Mol Biol 1999; 285: 1441-1455.
76. Valadao AF, Fantappie MR, LoVerde PT, Pena SD, Rumjanek FD, Franco GR. Y-box binding protein from Schistosoma mansoni: interaction with DNA and RNA. Mol Biochem Parasitol 2002; 125: 47-57.
77. Mertens PR, Harendza S, Pollock AS, Lovett DH. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 1997; 272: 22905-22912.
78. Li XY, Hooft van Huijsduijnen R, Mantovani R, Benoist C, Mathis D. Intron-exon organization of the NF-Y genes. Tissue-specific splicing modifies an activation domain. J Biol Chem 1992; 267: 8984-8990.
79. di Silvio A, Imbriano C, Mantovani R. Dissection of the NF-Y transcriptional activation potential. Nucleic Acids Res 1999; 27: 2578-2584.
80. Hu Q, Maity SN. Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes. J Biol Chem 2000; 275: 4435-4444.
81. Caretti G, Cocchiarella F, Sidoli C, Villard J, Peretti M, Reith W et al. Dissection of functional NF-Y-RFX cooperative interactions on the MHC class II Ea promoter. J Mol Biol 2000; 302: 539-552.
82. Ge Y, Jensen TL, Matherly LH, Taub JW. Synergistic regulation of human cystathioninebeta-synthase-1b promoter by transcription factors NF-YA isoforms and Sp1. Biochim Biophys Acta 2002; 1579: 73-80.
83. Domashenko AD, Danet-Desnoyers G, Aron A, Carroll MP, Emerson SG. TAT-mediated transduction of NF-Ya peptide induces the ex vivo proliferation and engraftment potential of human hematopoietic progenitor cells. Blood 2010; 116: 2676-2683.
84. Dolfini D, Minuzzo M, Pavesi G, Mantovani R. The short isoform of NF-YA belongs to the ES cell transcription factor circuitry. Stem Cells 2012; 30: 2450-2459.
85. Song B, Young CS. Functional analysis of the CAAT box in the major late promoter of the subgroup C human adenoviruses. J Virol 1998; 72: 3213-3220.
86. Sibinga NE, Wang H, Perrella MA, Endege WO, Patterson C, Yoshizumi M et al. Interferon-gamma-mediated inhibition of cyclin A gene transcription is independent of individual cis-acting elements in the cyclin A promoter. J Biol Chem 1999; 274: 12139-12146.
87. Nenoi M, Ichimura S, Mita K, Yukawa O, Cartwright IL. Regulation of the catalase gene promoter by Sp1, CCAAT-recognizing factors, and a WT1/Egr-related factor in hydrogen peroxide-resistant HP100 cells. Cancer Res 2001; 61: 5885-5894.
88. Grimm M, Spiecker M, De Caterina R, Shin WS, Liao JK. Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants. J Biol Chem 2002; 277: 26460-26467.
89. Lagor WR, de Groh ED, Ness GC. Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl-CoA reductase promoter. J Biol Chem 2005; 280: 36601-36608.
90. Leclerc GJ, Leclerc GM, Kinser TT, Barredo JC. Analysis of folylpoly-gamma-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells. BMC Cancer 2006; 6: 132.
91. Landsberger N, Wolffe AP. Role of chromatin and Xenopus laevis heat shock transcription factor in regulation of transcription from the X. laevis hsp70 promoter in vivo. Mol Cell Biol 1995; 15: 6013-6024.
92. Li Q, Herrler M, Landsberger N, Kaludov N, Ogryzko VV, Nakatani Y et al. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J 1998; 17: 6300-6315.
93. Dolfini D, Gatta R, Mantovani R. NF-Y and the transcriptional activation of CCAAT promoters. Crit Rev Biochem Mol Biol 2012; 47: 29-49.
94. Stein U, Jurchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermiainduced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001; 276: 28562-28569.
95. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003; 22: 7496-7511.
96. Asakuno K, Kohno K, Uchiumi T, Kubo T, Sato S, Isono M et al. Involvement of a DNA binding protein, MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D. Biochem Biophys Res Commun 1994; 199: 1428-1435.
97. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M et al. Role of the human Y boxbinding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56: 4224-4228.
98. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998; 273: 5997-6000.
99. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 447-450.
100. Vaiman AV, Stromskaya TP, Rybalkina EY, Sorokin AV, Guryanov SG, Zabotina TN et al. Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells. Biochemistry 2006; 71: 146-154.
101. Kaszubiak A, Kupstat A, Muller U, Hausmann R, Holm PS, Lage H. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem Biophys Res Commun 2007; 357: 295-301.
102. Goldsmith ME, Madden MJ, Morrow CS, Cowan. KH. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem 1993; 268: 5856-5860.
103. Sundseth R, MacDonald G, Ting J, King AC. DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 1997; 51: 963-971.
104. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998; 18: 4377-4384.
105. Hu Z, Jin S, Scotto KW. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 2000a; 275: 2979-2985.
106. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H. HMN-176 an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res 2003; 63: 6942-6947.
107. Okamura H, Yoshida K, Sasaki E, Morimoto H, Haneji T. Transcription factor NF-Y regulates mdr1 expression through binding to inverted CCAAT sequence in drug-resistant human squamous carcinoma cells. Int J Oncol 2004; 25: 1031-1037.
108. Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res 2010; 70: 8726-8735.
109. Xu Y, Jiang Z, Yin P, Li Q, Liu J. Role for class I histone deacetylases in multidrug resistance. Exp Cell Res 2012; 318: 177-186.
110. Chattopadhyay R, Das S, Maiti AK, Boldogh I, Xie J, Hazra TK et al. Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. Mol Cell Biol 2008; 28: 7066-7080.
111. Sengupta S, Mantha AK, Mitra S, Bhakat KK. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 2011; 30: 482-493.
112. Nakshatri H, Bhat-Nakshatri P, Currie RA. Subunit association and DNA binding activity of the heterotrimeric transcription factor NF-Y is regulated by cellular redox. J Biol Chem 1996; 271: 28784-28791.
113. Kauffmann HM, Vorderstemann B, Schrenk D. Basal expression of the rat, but not of the human, multidrug resistance protein 2 (MRP2) gene is mediated by CBF/NF-Y and Sp1 promoter-binding sites. Toxicology 2001; 167: 25-35.
114. Geier A, Mertens PR, Gerloff T, Dietrich CG, En-Nia A, Kullak-Ublick GA et al. Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Y-box protein 1. Biochem Biophys Res Commun 2003; 309: 612-618.
115. En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem 2005; 280: 7702-7711.
116. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I et al. YB-1 as a cell cycleregulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003; 278: 27988-27996.
117. Farina A, Manni I, Fontemaggi G, Tiainen M, Cenciarelli C, Bellorini M et al. Downregulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex. Oncogene 1999; 18: 2818-2827.
118. Gurtner A, Manni I, Fuschi P, Mantovani R, Guadagni F, Sacchi A et al. Requirement for down-regulation of the CCAAT-binding activity of the NF-Y transcription factor during skeletal muscle differentiation. Mol Biol Cell 2003; 14: 2706-2715.
119. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006; 66: 4872-4879.
120. Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A et al. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 2009; 28: 2406-2418.
121. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009; 28: 1421-1431.
122. To K, Fotovati A, Reipas KM, Law JH, Hu K,Wang J et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010; 70: 2840-2851.
123. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL et al. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst 2012; 104: 133-146.
124. Benatti P, Dolfini D, Vigano MA, Ravo M, Weisz A, Imbriano C. Specific inhibition of NF-Y subunits triggers different cell proliferation defects. Nucleic Acids Res 2011; 39: 5356-5368.
125. Benatti P, Basile V, Merico D, Fantoni LI, Tagliafico E, Imbriano C. A balance between NF-Y and p53 governs the pro-and anti-apoptotic transcriptional response. Nucleic Acids Res 2008; 36: 1415-1428.
126. Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, Berquin IM et al. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 2012; 31: 4434-4436.
127. Dolfini D, Mantovani R. YB-1 (YBX1) does not bind to the Y/CCAAT box in vivo. Oncogene 2012; e-pub ahead of print 19 November 2012; doi:10.1038/onc. 2012.521.
128. Frontini M, Imbriano C, Manni I, Mantovani R. Cell cycle regulation of NF-YC nuclear localization. Cell Cycle 2004; 3: 217-222.
129. Nardini M, Gnesutta N, Donati G, Gatta R, Forni C, Fossati A et al. NF-Y is a sequencespecific transcription factor displaying histone-like DNA binding and H2B-like ubiquitination. Cell 2013; 152: 132-143.
130. Davies AH, Dunn SE. YB-1 drives preneoplastic progression: insight into opportunities for cancer prevention. Oncotarget 2011; 2: 401-406.
131. Imbriano C, Gnesutta N, Mantovani R. The NF-Y/p53 liaison: well beyond repression. BBA Rev Cancer 2012; 1825: 131-139.
132. Tiwari VK, Stadler MB, Wirbelauer C, Paro R, Schubeler D, Beisel C. A chromatinmodifying function of JNK during stem cell differentiation. Nat Genet 2011; 44: 94-100.
133. Costessi A, Mahrour N, Tijchon E, Stunnenberg R, Stoel MA, Jansen PW et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J 2011; 30: 3786-3798.
134. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15: 402-415.
135. Evdokimova V, Tognon C, Ng T, Sorensen PH. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009; 8: 2901-2906.
136. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
137. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet 2010; 6: e1001231.
138. Soop T, Nashchekin D, Zhao J, Sun X, Alzhanova-Ericsson AT, Bjorkroth B et al. J Cell Sci 2003; 116: 1493-1503.
139. Kornblihtt AR. Promoter usage and alternative splicing. Curr Opin Cell Biol 2005; 17: 262-268.
140. Allemand E, Batsché E, Muchardt C. Splicing, transcription, and chromatin: a ménage à trois. Curr Opin Genet Dev 2008; 18: 145-151.